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http://dxObjectives:A novel bioprosthetic tricuspid valve was constructed from an acellular extracellular matrix (ECM)
bioscaffold. The valve’s mechanical functionality and potential for histologic regeneration was evaluated in an
ovine model.
Methods: The native tricuspid valves of 4 domestic sheep were excised and replaced with bioprosthetic valves
constructed from the ECMbioscaffoldmaterial shaped into the form of a tube. In vivo function was assessed over
time by transthoracic echocardiography. Animals were euthanized at 3, 5, 8, and 12 months after valve implan-
tation, and explanted valves were examined for gross morphology and by qualitative histopathologic analysis.
Results:All 4 sheep survived until the specified date. Forward flow by echocardiography was normal with trivial
to mild regurgitation. Annular morphology and mobility of the leaflets appeared normal with excellent leaflet
coaptation. Explanted valves were grossly normal at all time points and showed evidence of progressive tissue
remodeling and integration at the host-tissue interface. Histopathologic analysis demonstrated massive host-cell
infiltration, structural reorganization of the ECM bioscaffold, elastin generation at the annulus by 3 months, and
increased collagen organization and glycosaminoglycan presence in the leaflets by 5 months, with no evidence
of foreign body response.
Conclusions:When implanted in the form of a tubular valve, the acellular ECM bioscaffold demonstrates feasi-
bility as a biomechanically sound bioprosthetic tricuspid valve replacement with evidence of progressive endo-
thelialization and constructive tissue remodeling. (J Thorac Cardiovasc Surg 2014;148:333-40)Supplemental material is available online.Video clip is available online.
There is growing interest in the development of a tissue-
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Svalve depends on both the bioregenerative potential of the
material used for the valve and the design of the valve.
One promising material for the construction of such
a valve is an acellular bioscaffold composed of non-
crosslinked extracellular matrix (ECM) derived from
porcine small intestinal submucosa (SIS). Preparations of
this material have shown utility as a bioresorbable surgical
material capable of in vivo cellular recruitment and repopu-
lation in awide variety of tissues, including cardiac tissue.2-9
Growth potential has previously been demonstrated in a
study that used SIS as an interpositional vena cava graft
in a growing piglet. Both longitudinal (147%) and
circumferential (184%) growth of the SIS graft were
observed over a 3-month time period.10
When implanted in the body, proteolytic degradation of
the ECM scaffold by immunomodulatory, proremodeling
macrophages produces biochemical cues that attract pro-
genitor cells and, in concert with the surrounding biome-
chanical and fluid-dynamic environment, induce
progenitor-cell proliferation and phenotypic matura-
tion.4,11-13 Products of matrix degradation also confer
antimicrobial properties on the ECM material,14 and lack
of crosslinking reduces its propensity for inflammation
and calcification.4,15,16 Furthermore, although the
galactosyl-alpha(1,3)galactose epitope has been identified
in decellularized SIS,17 its presence has not been found to
produce an adverse, proinflammatory cellular response
either in cell culture18 or in a nonhuman primate model.19rdiovascular Surgery c Volume 148, Number 1 333
Abbreviations and Acronyms
ECM ¼ extracellular matrix
eNOS ¼ endothelial nitric oxide synthase
SIS ¼ small intestinal submucosa
SMA ¼ smooth muscle actin
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prosthetic heart valve, experimental and clinical studies
over the past 2 decades have demonstrated the superiority
of a tubular design in terms of restoring normal transpros-
thetic flow dynamics and stress distribution on the valve
leaflets, regardless of the type of tissue or other material
used to construct such tubular valves.20
In this study, we combined a tubular valve design and an
acellular ECM bioscaffold to determine whether or not this
combination of valve design and biomaterial could function
long-term in an ovine model while remodeling grossly and
histologically into a bioprosthetic valve with characteristics
similar to those of a native tricuspid valve.MATERIALS AND METHODS
Bioprosthetic Valve Materials and Design
The bioscaffold used to construct the tubular prosthetic replacement
valves was an acellular, noncrosslinked, press-lyophilized, 2-ply sheet of
ECM derived from porcine SIS (CorMatrix ECM; CorMatrix Cardiovascu-
lar Inc, Roswell, Ga). A flat sheet of the ECM was converted into the
desired tubular shape by suturing its edges together using 6-0 polydioxa-
none absorbable suture (PDS II; Ethicon, Somerville, NJ), resulting in a
tube approximately 30 mm long with a 28 mm inner diameter (Figure E1).
Animals and Surgical Procedure
The procedure and animals used in this study were approved by the
Saint Joseph’s Translational Research Institute Institutional Animal Care
and Use Committee. All animals received humane care in compliance
with The Guide for the Care and Use of Laboratory Animals published
by the National Institutes of Health.
Animals (Western Range wether sheep weighing 46.8-61.6 kg) were
anesthetized with intravenous propofol (100-300 mg) or ketamine and xy-
lazine and inhaled isoflurane, with atropine (3-4 mL) and flunixin (100
mg). A right lateral thoracotomy was performed and the pericardium
was opened longitudinally approximately 2 cm anterior to the right
phrenic nerve. Ampicillin (1000 mg bolus), gentamicin (200 mg bolus),
and prednisolone/prednisone (100 mg bolus) were administered intrao-
peratively. Heparin (5000 U) was administered 1 to 2 minutes before
initiation of cardiopulmonary bypass. After cardiopulmonary bypass
was instituted, a right atriotomy was performed and the entire native
tricuspid valve apparatus, including its 3 leaflets and all chordae tendi-
neae, was excised. Using 5-0 polydioxanone, the distal end of the
ECM tube was sutured to each of the 3 papillary muscles, and the prox-
imal end of the ECM tube was sutured circumferentially to the tricuspid
valve annulus, as shown in Figure 1. Following visual intraoperative
confirmation of valve competence and leaflet coaptation, the right atriot-
omy was closed with 3-0 polypropylene suture and the animals were
weaned from cardiopulmonary bypass. Function of the newly implanted
tricuspid valve bioprosthesis was evaluated immediately using epicardial
echocardiography. The pericardium and right thoracotomy were then
closed and the animals were allowed to recuperate. Transvalvular334 The Journal of Thoracic and Cardiovascular Surggradient, pulmonary artery systolic diameter, leaflet mobility, and leaflet
thickness of the implanted tricuspid valve bioprostheses were subse-
quently evaluated by transthoracic echocardiography at 1 week and 1,
5, 8, and 12 months postoperatively.
Valve Explantation, Sample Preparation, and
Histopathology
The animals were evaluated by Doppler ultrasound at 3, 5, 8, and 12
months after valve implantation and were then heparinized and eutha-
nized. The bioprosthetic tricuspid valves were excised en bloc to
include the papillary muscles and both the atrial and ventricular tissue
encompassing the native annulus. The tricuspid valve prostheses were
immediately inspected for any thrombus, leaflet tears, valve rupture,
or calcification. Each valve was then rinsed with saline, fixed in 10%
neutral buffered formalin, paraffin embedded, sectioned, and examined
microscopically for qualitative evidence of tissue integration, native
cellular infiltration, inflammatory response, calcium deposition, endo-
thelial cell coverage, and ECM organization. Vital stains in preparation
for histologic study included hematoxylin and eosin to show cellular
infiltration, von Kossa to show mineralization, Verhoeff Masson and
Movat pentachrome for ECM organization, CD31 and endothelial nitric
oxide synthase (eNOS) to identify possible endothelial cell phenotype,
and smooth muscle actin (SMA) and vimentin to identify possible inter-
stitial cell phenotype. A comprehensive quantitative or time-course
analysis of cell types and numbers was not possible within the scope
of this study.
Data Analysis
Due to the limited number of test animals no statistical analysis was
performed.
RESULTS
Implantation and In-Vivo Observations
Four sheep underwent direct surgical implantation of a
tubular ECM bioprosthetic valve in the tricuspid position
after complete excision of the native tricuspid valve. The
surgical procedure was successful and without complica-
tions in all 4 animals, although 2 required intraoperative
cardioversion. All animals recovered from the procedure
and lived until their scheduled euthanasia dates. Normal ac-
tivity, appetite, and weight gain were recorded in each ani-
mal throughout the study duration and there were no
untoward health concerns.
Echocardiography
Serial transthoracic echocardiography assessment
demonstrated that bioprosthetic tricuspid valve function,
leaflet mobility, and leaflet thickness were essentially
normal in all animals except in the 12-month animal, which
was noted to have 1 static leaflet between the 1- and 8-
month time intervals (Table 1). This finding was not associ-
ated with any increase in valvular insufficiency and the
static leaflet had regained its normal mobility by the 12-
month study interval.
At variable time intervals, some of the animals ex-
hibited trivial to mild backflow through the valve after
closure. Echocardiography showed complete coaptation
of the leaflets with no leaflet prolapse (Figure 2 andery c July 2014
FIGURE 1. Procedural photographs of the tricuspid valve implantation. A, View from the atrial side shows initial placement of the 3 papillary muscle
attachments (valve body and attachment denoted by white arrows). B, View from the ventricular side shows all 3 papillary muscle attachments (denoted
by white circles). C, View from the atrial side showing the implanted valve annulus.
Fallon et al Evolving Technology/Basic ScienceVideos 1-4). It has been shown previously that the degree
of apparent valvular insufficiency in these tubular valves
may be exaggerated on echocardiography because of the
residual fluid that is trapped within the cylinder when
the valves are open. This closing volume fluid may be
ejected retrograde upon valve closure, which on echocar-
diography could appear to be regurgitant volume when
there is no actual regurgitation present.
Gross Characteristics of Explanted Tubular ECM
Valves
The explanted bioprosthetic ECM valves exhibited the
typical trileaflet structure characteristic of a native tricuspid
valve (Figure 3). Grossly, the margins of the bioprosthetic
ECM valves had integrated with the native valve annulus
and the only visual evidence in this location that this was
an implanted valve was the slight scarring at the site ofTABLE 1. Summary of transthoracic echocardiography observations in
tricuspid valve*
Animal No. Assessment time point, wk Regurgitation
2948 0 Mild
1 Mild
4 Mild
12 Mild
2981 0 Mild
1 Mild
4 Mild
20 Mild to moderate
2969 0 Mild
20 None
24 Mild
32 Mild
2966 0 None
1 Mild
4 None
24 None
32 None
40 None
48 None
*See also Videos 1-4.
The Journal of Thoracic and Caeach of the annular sutures. By 5 and 8months, the papillary
muscle attachment sites looked similar to those in a native
tricuspid valve (Figure 4). At 8 months, the surfaces of
the leaflets were smooth and glistening, with a tissue-like
appearance over an estimated 75% of their surface. At 12
months, the tissue-like appearance had extended to the
entire leaflet. In the animal that survived until 12 months,
a small tissue tag was noted on the papillary end of the ante-
rior leaflet (Figure 4, D). Histologic investigation showed
that this was an adherent, organized thrombus (Figure E2).
Histopathology
Qualitative histologic examination of the explanted
ECM bioprosthetic valves showed diffuse cellular infiltra-
tion, presumably from the surrounding host tissue, in the
3-month explanted valve, with elastin formation evident
at the annulus (Figure 5). Although not directly quantified,4 sheep implanted with a tubular extracellular matrix bioprosthetic
Comments
Mobility and function of the leaflets appear normal. Leaflet
coaptation looks sufficient and annulus appears morphologically
normal. Normal forward flow with mild to trivial regurgitation
Mobility and function of the leaflets appears normal. Leaflet
coaptation looks sufficient and annulus appears morphologically
normal. Normal forward flow with a mild level of regurgitation
Mobility and function of the leaflets appears normal. Leaflet
coaptation looks sufficient and annulus appears morphologically
normal. Normal forward flow with a mild to no regurgitation
Mobility and function of the leaflets appears normal. Leaflet
coaptation looks sufficient and annulus appears morphologically
normal. Normal forward flow with no regurgitation noted except
at the 1-wk time point
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FIGURE 2. A, Doppler echocardiography of implanted CorMatrix ECM tricuspid valve (CorMatrix Cardiovascular, Inc, Roswell, GA) for 5-month animal
(No. 2981) immediately postoperatively in the open position. B, Doppler echocardiography of implanted CorMatrix ECM tricuspid valves for 5-month
animal (No. 2981) immediately postoperatively in the closed position. C, Doppler echocardiography of implanted CorMatrix ECM tricuspid valve for
12-month animal (No. 2966) 8 months postoperatively with the valve in the open position. D, Doppler echocardiography of implanted CorMatrix ECM
tricuspid valve for 12-month animal (No. 2966) immediately postoperatively in the closed position.
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the valve leaflet, and vimentin-positive cells were inter-
spersed throughout the center of the leaflet. There was
limited evidence of mineralization associated with the su-
tures at the interface between the bioprosthesis and the
annulus as demonstrated by von Kossa staining (Figure E3).
In the 5-month explanted valve, collagen organization
appeared to increase and glycosaminoglycans appeared
distributed throughout the middle of the leaflet. Hematoxy-
lin and eosin stains suggested the presence of inflammatory
cells localized to the suture sites. Similarly, von Kossa
staining showed small, calcific deposits associated with
the suture line in the septal cusp. No von Kossa staining
was observed in the posterior or anterior leaflets. By micro-
scopic visual inspection, an apparently continuous endothe-
lial monolayer lined the atrialis and fibrosa of the posterior
leaflet (Figure E3) although the extent of endothelialization
was not directly quantified. An apparently continuous endo-
thelial monolayer lined the atrialis of the septal and anterior
leaflets and discontinuous endothelial cells lined the fibrosa.
The endothelial cells were also faintly positive for eNOS
activity (Figure 5) along the atrialis. The interstitial cells
were positive for vimentin with some colocalization with
SMA staining.
In the 8-month explanted valve, an apparently continuous
endothelial monolayer was observed lining the atrialis of
the anterior and posterior leaflets, with a discontinuous336 The Journal of Thoracic and Cardiovascular Surgendothelium lining the fibrosa of the septal leaflet. The
endothelial cells stained for both CD31 and eNOS on the at-
rialis. No positive von Kossa staining was observed in the
anterior leaflet; however, there was positive von Kossa
staining observed in the septal leaflet and posterior leaflet
indicating that some calcium deposition had occurred by
8 months. Vimentin-positive cells were located in the center
of the leaflet with some colocalization with SMA. SMA-
positive cells were seen nearer to the atrialis side of the
leaflet and in the wall of newly formed vessels.
In the 12-month explanted valve, an apparently contin-
uous endothelial monolayer was observed lining the atrialis
of anterior and posterior leaflets. These cells were positive
for CD31 and eNOS. No von Kossa staining was observed
in the anterior leaflet. However, there were small, calcific
deposits associated with the suture line in the posterior
leaflet shown in the von Kossa stain. Movat pentachrome
staining for ECM organization showed a defined, layered
structure in the new valve leaflets in which collagen (yel-
low) was organized in the outer layer with elastin (black)
deposition on the atrial side and glycosaminoglycans
(blue-green) distributed throughout the middle of the leaf-
lets. Similar to the 8-month time point, vimentin-positive
cells were located in the center of the leaflet, with increased
colocalization with SMA. SMA-positive/vimentin-negative
cells were also seen nearer to the atrialis side of the leaflet
and in the wall of newly formed vessels.ery c July 2014
FIGURE 3. Gross appearance (atrial aspect) of explanted, saline-insufflated extracellular matrixbioprosthetic tricuspid valves. A, After 3 months of
implantation. B, After 5 months of implantation. C, After 8 months of implantation. D, After 12 months of implantation.
Fallon et al Evolving Technology/Basic ScienceDISCUSSION
The first objective of our study was to determine if the
combination of a tubular valve design and this specificFIGURE 4. Gross appearance of papillary muscle attachment formation (ventri
B, At 5 months of implantation. C, At 8 months of implantation. D, At 12 mon
The Journal of Thoracic and Caacellular ECM bioscaffold material would provide the crit-
ical elements necessary to allow the resulting valve bio-
prosthesis to function optimally early after implantation,cular aspect) in explants from ovine model. A, At 3 months of implantation.
ths of implantation.
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FIGURE 5. Microscopic histopathologic analysis of explanted extracellular matrix bioprosthetic or native ovine tricuspid valves. A, Movat pentachrome
staining at 3 months (animal No. 2948, valve annulus, 403). B, CD31/endothelial nitric oxide synthase (eNOS) immunohistochemistry (IHC) staining at 3
months (animal No. 2948, posterior leaflet, 2003). C, Vimentin/smooth muscle actin (SMA) IHC staining at 3 months (animal No. 2948, posterior leaflet,
4003). D, Movat pentachrome staining at 5 months (animal No. 2981, anterior leaflet, 2003). E, CD31/eNOS IHC staining at 5 months (animal No. 2981,
anterior leaflet, 1003). F, Vimentin/SMA IHC staining at 5 months (animal No. 2981, anterior leaflet, 2003). G, Movat pentachrome staining at 8 months
(animal No. 2969, anterior leaflet, 1003). H, CD31/eNOS IHC staining at 8 months (animal No. 2969, anterior leaflet, 1003). I, Vimentin/SMA IHC stain-
ing at 8 months (animal No. 2969, anterior leaflet, 2003). J. Movat pentachrome staining at 12 months (animal No. 2966, posterior leaflet, 1003). K, CD31/
eNOS IHC staining at 12 months (animal No. 2966, posterior leaflet, 1003). L, Vimentin/SMA IHC staining at 12 months (animal No. 2966, posterior
leaflet, 1003). M,Movat pentachrome staining of native ovine tricuspid valve (anterior leaflet, 1003). N, CD31/eNOS IHC staining of native valve (anterior
leaflet, 1003). O, Vimentin/SMA IHC staining of native valve (anterior leaflet, 1003). In images A, D, G, J, andM, light blue is glycosaminoglycans, yellow
is collagen, red is muscle, and black is elastin. In images B, E, H, K, and N, brown is CD31 and red is smoothmuscle actin. In images C, F, I, L, and O, brown
is vimentin and red is smooth muscle actin.
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Sand then remodel into a valve made of cellularized tissue
over a period of the next several months. Unlike materials
used previously for the construction of tubular heart
valves,20 the biomaterial chosen for the construction of
this particular valve exhibits unique properties that could
theoretically lead to early valve failure. For example, in
other settings, the ECM bioscaffold has been shown to be
replaced by native host tissue as the biological degenera-
tion, resorption, and remodeling of the ECM progresses.3-10
Therefore, a central question was whether or not this
material would maintain sufficient strength during the
time-dependent interaction between ECM degradation and
tissue remodeling to function as a bioprosthetic heart valve.
This feasibility study demonstrated that the ECM bio-
scaffold was strong enough to serve as a functional tricuspid
valve in sheep immediately after implantation. In addition,
despite the time-dependent resorption of the ECM and
simultaneous infiltration by host cells, the overall strength
of the bioprosthesis remained sufficient to preclude valve
failure for at least 12 months after implantation, by which
time the original ECM biomaterial had largely disappeared
and the valve prosthesis had converted to cellularized valve
tissue. Serial, in vivo echocardiography showed that the
tubular ECM bioprosthetic tricuspid valve implant func-
tioned normally both early and late after implantation and
that it retained normal leaflet thickness, mobility, and coap-
tation throughout the 12-month study period. Morphologi-
cally, the tubular ECM bioprosthetic valve showed a
striking resemblance to a normal native tricuspid valve
(by echocardiography). It should be noted that this anatomic
similarity to the normal native tricuspid valve seen on echo-
cardiography is due to the tubular design of the valve20 and
not to the biological properties of the ECMmaterial used to
construct the valve, once again supporting the principle that
form follows function (Figure 3).
Of considerable interest was the macroscopic and micro-
scopic evidence of cellular integration at the interface be-
tween the ECM bioprosthetic valve material and the
annular tissue to which it was sutured. Despite the use of
absorbable suture material that was expected to degrade
completely within 180 days of implantation, dehiscence
of the implanted ECM bioprosthetic valve was not observed
at any time interval. Gross pathologic analysis at all time in-
tervals showed gradual disappearance of a defined suture
line consistent with ingrowth of host cells (Figure 3). More-
over, histopathologic analysis demonstrated massive infil-
tration of host cells into the implanted ECM bioprosthetic
valve. The abundance of elastin generation at the valve
annulus and glycosaminoglycan formation throughout the
implanted valve material (Figure 5) suggest that the infil-
trating host cells were actively remodeling their environ-
ment to form an extracellular matrix more similar in
structure to that found within the tricuspid valve environ-
ment. Although a comprehensive quantitation of cellThe Journal of Thoracic and Canumbers and types was beyond the scope of this study,
immunohistochemical staining suggested that the replace-
ment cells were predominantly of an endothelial and valve
interstitial-cell phenotype and not a fibrotic phenotype,
providing further evidence of a constructive regenerative
process.
Histologic comparison was suggestive of similarities be-
tween the implanted and native sheep tricuspid valves
(Figure 5). Although elastin in the ECM valvewas localized
mainly in the atrialis instead of more universally as in the
native valve, it was encouraging that elastin was generated
in the prosthetic valve. The glycosaminoglycan distribution
in the interstitial region also appeared qualitatively similar.
The endothelial layer in the native valve stained only faintly
for eNOS and did not stain for CD31, which may be due to
differences in vessel endothelial cells and tricuspid valve
endothelial cells because the positive control (sheep artery)
did stain for CD31. The distribution of vimentin-positive
interstitial cells with colocalized SMA staining was also
similar.
Although synthetic and crosslinked biomaterials were
not directly evaluated in this study, previous studies have
shown that the cellular response to those types of materials
favors an inflammatory response, foreign-body response, or
encapsulation in fibrotic scar tissue.1,21,22 To our
knowledge, no other prosthetic valve material has been
shown to recellularize or undergo the apparent biological
integration observed in this study.
With the exception of a minimal degree of calcification
associated with the suture line, we found no histopatholog-
ic evidence of a destructive foreign-body response detected
in this study, nor was there evidence of calcification by
functional echocardiogram. This is of particular interest
because sheep exhibit a high propensity for calcification
of implanted prosthetic tissue valves, especially in the
tricuspid valve position.23 Indeed, this exaggerated predis-
position toward calcification is 1 reason why the US Food
and Drug Administration recommends the replacement of
tricuspid valves in sheep as a standard animal model to
evaluate the propensity of artificial tissue valves to calcify
in vivo.
Most tissue-engineering approaches to heart valve
replacement have involved preseeding valve-shaped
bioscaffolds with stem or progenitor cells in vitro,
and then implanting them into living animals for
further integration.1,21,22 Our use of an acellular
bioscaffold for bioprosthetic valve construction represents
a fundamentally different and much simpler approach,
designed to take advantage of extracellular matrix biology
and the ready availability of native stem cells and other
progenitor cells already present within the host. Our study
is consistent with previous studies showing that the
degradation of implanted decellularized SIS attracts
progenitor cells from the surrounding host tissue and therdiovascular Surgery c Volume 148, Number 1 339
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quantify the cells repopulating the ECM bioscaffold, and
to determine their origin, lineage, and functionality, when
the ECM is used as a material for bioprosthetic valve
construction.Study Limitations
As a feasibility study, the principal limitations are the
minimal sample size, the relatively short period of observa-
tion, and the qualitative nature of the histopathologic obser-
vations. Whereas the preliminary data presented here were
suggestive of the presence of cells involved in valve struc-
ture and function, the exact number of cells and cell types
that expressed CD31, vimentin, SMA, eNOS, and elastin
were not determined and it is not possible to conclude if
the remodeled tissue was ‘‘native-like’’ from these data.
Furthermore, no conclusions can be drawn regarding the
consistency of the observed regenerative behavior or the
long-term durability or function of the tubular ECM bio-
prosthetic valve on the basis of this study.
Also, the use of an ovine model, although optimal for
early detection of calcification, does have limitations with
respect to differences in the coagulation cascade and in ab-
sorption of anticoagulant medications. It has been reported
that because sheep are ruminants and therefore have
different stomach acidity than humans, they may not absorb
medications such as acetylsalicylic acid and clopidogrel as
efficiently. Thus, although acetylsalicylic acid and clopi-
dogrel were administered for the duration of the study, the
extent of absorption is not known, and is probably variable.
Thus, it is likely not at the same concentration as what
would be administered clinically. The organized thrombus
noted at 12 months (Figure 3, D, and E2) may be a result
of this poor absorption.
Despite these limitations, our results suggest that it may
be possible to develop artificial replacement valves capable
of biological integration with the surrounding host tissue.
Additional animal studies are currently in progress with
longer observation times and larger numbers of animals,
with the objective of determining the parameters necessary
to construct tubular bioprosthetic ECM valves suitable for
clinical use. These studies are expected to further charac-
terize the potential for the tubular ECM bioprosthetic con-
structs to remodel into valves that are similar, grossly and
histologically, to native, normally functioning host valves
without calcification and with prolonged durability in com-
parison to currently available commercial tissue valve pros-
theses. Such native valve regeneration would be expected to
improve outcomes for patients being treated for valve
disease.340 The Journal of Thoracic and Cardiovascular SurgThe authors thank Jeanne McAdara-Berkowitz, PhD, for pro-
fessional assistance with preparation of the manuscript.
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FIGURE E1. Tubular extracellular matrix bioprosthetic valve construct before implantation.
FIGURE E2. Hematoxylin and eosin staining of the tissue tag from the 12-month animal (No. 2966), identifying it as an adherent, organized thrombus.
FIGURE E3. von Kossa staining of the valve sections showing mineralization at the suture for some of the valves. A, Staining after 5 months (animal No.
2981, papillary muscle connection). B, Staining at 8 months (animal No. 2969, anterior leaflet).
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